EGFR and neoplasm: In view of this, Choi et al. developed a CART.BiTE (an EGFRvIII specific CAR-T secreting EGFR-specific BiTE) and confirmed its ability to eradicate heterogeneous tumor cells in glioblastoma mouse models [50].